Implementing Contemporary Technology and Therapeutic Expertise, Croissance Clinical Research was initiated in 2013, with dedication to helping the client to achieve their ultimate goal. Croissance believes in ensuring that each clinical study is conducted in an ethical and compliant manner that offers the highest possible quality with clean and accurate data, meets international quality standards, cost-effectively on time and every time. Croissance is a full-service CRO offering services like Project management, Capacity building, Medical writing, Safety oversight, Quality assurance, Regulatory support, Clinical Data management and Biostatistics. Croissance is an experienced CRO offering its services for Phase II–IV, PMS, IIS and Epidemiology studies with a large network of investigators in public & private hospitals across India, Nepal, Africa. Croissance is an ISO 9001: 2015 & ISO 27001:2013 certified organization and a strong process-driven company.
Mr. Satish Marukurthi, Founder & CEO at Croissance Clinical Research has been largely involved in building, shaping and providing innovative strategies in the growth story of Croissance. He is a dynamic individual and under his leadership, Croissance grew from an Indian to an International CRO. He has been awarded the most prestigious award of the “Pharma Leaders Innovative Leadership in Clinical Research 2019” at Pharma Leaders Power Brand Awards 2019.
A highly respected Kenyan paediatrician and clinical pharmacologist, he serves as a member of the Expert Committee on Clinical Trials of the Pharmacy and Poisons Board, the regulatory authority under the Kenyan Ministry of Health. He has been instrumental in establishing the Malaria Diagnostic Centre of Excellence at KEMRI in Kisumu, significantly advancing diagnostic capabilities in the region. Through his leadership roles at KEMRI and CREATES (Strathmore University), active involvement in major clinical trials, and extensive scientific publications, he has made impactful contributions to malaria research and broader therapeutic science at both local and international levels. He continues to play a key role in clinical trials across Africa and beyond.
Dr. Jongo, former Head of the Bagamoyo Clinical Trials Unit (BCTU), led multiple vaccine and drug trials at IHI’s Bagamoyo site, including the first African trial demonstrating the safety of the P27A malaria vaccine candidate. Under his leadership, the scope of clinical research expanded to include diverse populations such as infants, children, and individuals living with HIV, significantly advancing inclusivity in malaria studies. A strong advocate for capacity building, he has mentored junior scientists, supported MSc and PhD training for colleagues, and contributed to establishing regulatory-grade clinical research platforms, including in Equatorial Guinea through collaborations with IHI.
Dr. Prof. Mutesa is a medical doctor (MD) and human geneticist (PhD) who previously served as Director General of the Medical Research Center under the Rwanda Biomedical Centre, Ministry of Health, where he coordinated research across national medical institutions. He currently serves as Principal Investigator on a major grant focused on HIV/HPV-related cancer prevention, pathogenesis, and treatment among HIV-positive women and key populations. Widely recognized both in Rwanda and internationally, he has made significant contributions to building genomic research infrastructure, mentoring future scientists, and advancing public health genomics and research capacity across East Africa. In 2024, he was honored with the African Prize for Lifetime Contribution in Human Genetics by the Human Genome Organisation (HUGO), acknowledging his decades-long pioneering work in genetics and genomics in Africa.
Dr. Aspinall is a highly experienced medical science research professional with a strong blend of academic, entrepreneurial, and international expertise. She previously served as Director of Research at the Medical University of Southern Africa, collaborating with pharmaceutical and vaccine companies to support their research and development programs, and has also been a member of the Regulatory Authority in South Africa. As the founder of the first private SMO network in South Africa and of Ardent Consulting, she has led and contributed to more than 200 clinical studies across early- and late-stage development in diverse therapeutic areas, including vaccines, infectious diseases, respiratory, and metabolic disorders. With extensive experience navigating complex regulatory environments, she has successfully facilitated timely approvals with SAHPRA. In addition, Dr. Aspinall owns a clinical research training company, where she focuses on upskilling professionals in the sector, driven by her passion for maintaining good clinical practice, optimizing clinical trials, and ensuring high-quality research outcomes.
In the last decade, Croissance has successfully delivered 125 clinical trials across different therapeutic areas and has managed data of more than 1.5 million pages. COVID taught the industry how to be agile and how clinical trials can be done in the most efficient ways even in a challenging situation. Croissance played a vital role by supporting multiple pharmaceutical companies in drug development and this war against the good of mankind through adapting to technology and executive clinical trials at the almost quality standards and within the quickest timelines. Over the years Croissance has developed vast experience & and expertise in certain therapeutic areas like Respiratory and Vaccines.
Our vision is to be the preferred Contract Research Organization (CRO) for clinical research services across the regions where we operate, by consistently delivering timely, high-quality, ethical, and cost-effective solutions to our clients. We leverage our global experience within a multinational environment while integrating deep local knowledge and expertise, enabling us to provide efficient, compliant, and culturally aligned services that drive successful clinical outcomes.
Croissance Clinical Research is fueled by morals and principles like providing customer satisfaction with quality and integrity. Collaborating and keeping open communication for constant improvement. Being environmentally responsible, having ethical conduct.
In next 5 years Croissance wants to be seen as a leading CRO in vaccine trials and proudly serve its customer. The future will be digital and the team is turning the table around in terms of formulating the right set of processes, developing required skills, adapting to new technologies and platform that can help them work more efficiently. Focus is to venture newer territories and countries where there is high unmet need for vaccines. Work closely with the government agencies to streamline processes for smooth conduct of trials. Croissance is investing wisely to create an ecosystem that can generate quality real world data in a more efficient manner and help its client meet the study objective.
